Market Snapshot
| Study Period: | 2012-2026 |
| Base Year: | 2020 |
| Fastest Growing Market: | North America |
| Largest Market: | North America |
| CAGR: | 5.75 % |
|
Need a report that reflects how COVID-19 has impacted this market and its growth?
Market Overview
The diabetes care devices market was valued at USD 49 billion in 2020, and it is expected to reach USD 69 billion by 2026, registering a CAGR of 5.75% during the period of 2021- 2026 (henceforth referred to as the ‘forecast period’).
The significant growth in the market can be attributed to factors, such as the rising prevalence of diabetes and the increasing number of programs initiated by various health organizations related to health awareness. Currently, about 10% of all diabetes cases are Type-1 and the remaining are Type-2. As of 2020, North America accounted for a major share in the market, followed by Asia-Pacific. The increase in the number of diabetes patients is primarily due to increasing obesity among people caused by unhealthy diets and sedentary lifestyles. North America is anticipated to dominate the market during the forecast period, owing to the rising prevalence of obesity in the region. There has been a significant rise in insulin delivery systems technology, ranging from insulin injections to insulin pumps. Technological innovations and advancements offer many conveniences in measuring blood glucose levels. One such advancement in monitoring blood glucose levels is the continuous glucose monitoring devices.
Scope of the report
The Diabetes Care Devices Market is Segmented by Management Devices (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors), Monitoring Devices (Self-monitoring Blood Glucose and Continuous Glucose Monitoring), and Geography. The market study includes the following aspects:
| Monitoring Devices (Value and Volume, 2016 - 2026) | |||||
| |||||
|
| Management Devices (Value and Volume, 2016 - 2026) | |||||
| |||||
| Insulin Syringes | |||||
| Insulin Cartridges | |||||
| Disposable Pens | |||||
| Jet Injectors |
| Geography | ||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||
|
Key Market Trends
Increasing Diabetes Population Worldiwide
Approximately 4 million adults aged 20-79 years were estimated to die as a result of diabetes and its complications in 2020. This is equivalent to one death every eight seconds. Diabetes is estimated to be associated with 11.3% of global deaths from all causes among people in this age group. According to AACE (American Association of Clinical Endocrinologists), recent studies have shown that of those hospitalized for severe disease, 22.2% to 26.9% reported living with diabetes. Diabetes and high glucose levels are associated with increased complications, respiratory failure, and mortality in hospitalized patients with Coronavirus. Diabetes is associated with many health complications. Comparing the population with and without diabetes, those with diabetes have a 300% increased risk of being hospitalized and thus incur more healthcare expenses compared to non-diabetic people. Due to the early age and longer diabetes duration, the youth is at risk of developing diabetes at a younger age, which lessens their quality of life, shortens life expectancy, and increases healthcare costs. Therefore, the incidence of diabetes is expected to increase over time. There is also a concern that diabetes may be occurring at a greater frequency in youth and young adults due to the current lifestyle and technological advancements, increasing the adoption of Diabetes care Devices.
To understand key trends, Download Sample Report
North America Holds Highest Market Share in Year 2020
North America recorded more than USD 19 billion in revenue in 2020, which is expected to further increase with a CAGR of more than 7% during the forecast period. This is primarily due to the increasing diabetes population in North America, due to stress, unhealthy diets, and obesity. In North America, there are more than 29 million diabetes patients, and this number is expected to increase to 33 million by 2026. The United States alone recorded over 26 million diabetes patients in 2020. In North America, the United States holds a major share in the diabetes care devices market. Diabetes care devices market growth in this region is also supported by favorable government reimbursement policies and advanced healthcare infrastructure. Countries in Southeast Asia are expected to generate higher demand in the coming years, primarily due to the initiatives undertaken by the local government and health organizations to spread awareness about diabetes devices. The diabetes population in this region has increased at an alarming rate over the past decade. The major challenge faced by the diabetes care devices market in the emerging economies of the Asia-Pacific region is the lack of healthcare infrastructure and centralized supply chains, which result in price variations.
To understand geography trends, Download Sample Report
Competitive Landscape
The Diabetes Care Devices market is moderately fragmented, with few significant and generic players. The CGM devices market is dominated by few major players, like Dexcom Medtronics Abbott. The market for BGM devices comprises more generic players. The intensity of competition among the players is high, as each player is striving to develop a new device and offer it at competitive pricing. Furthermore, in order to increase their market shares, players are tapping into new markets, especially the emerging economies where the demand is very high compared to the supply. one of the recent developments in the diabetes care devices market include:
- In September 2020, Medtronics has received United States Food and Drug Administration (FDA) approval of its MiniMed™ 770G hybrid closed loop system. This insulin pump system offers the company’s most advanced SmartGuard™ technology, as featured in the MiniMed™ 670G system, with the added benefits of smartphone connectivity and an expanded age indication to children as young as 2.
RECENT DEVELOPMENTS
- In June 2020, Tandem Diabetes Care announced that they have finalized an agreement to develop and commercialize integrated diabetes solutions that combine Abbott's continuous glucose monitoring (CGM) technology with Tandem's innovative insulin delivery systems to provide more options for people to manage their diabetes.
- In July 2020, Medtronic Introduced MiniMed Mio Advance Infusion Set Enabling Fewer Insertion Steps for People with Diabetes in the United States. The MiniMed Mio Advance infusion set is the newest addition to the MiniMed portfolio of infusion sets and gives people using insulin pumps an optimal user experience with fewer steps.
Table of Contents
1. INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 Monitoring Devices (Value and Volume, 2016 - 2026)
5.1.1 Self-monitoring Blood Glucose
5.1.1.1 Glucometer Devices
5.1.1.2 Test Strips
5.1.1.3 Lancets
5.1.2 Continuous Glucose Monitoring
5.1.2.1 Sensors
5.1.2.2 Durables
5.2 Management Devices (Value and Volume, 2016 - 2026)
5.2.1 Insulin Pumps
5.2.1.1 Insulin Pump Device
5.2.1.2 Insulin Pump Reservoir
5.2.1.3 Infusion Set
5.2.2 Insulin Syringes
5.2.3 Insulin Cartridges
5.2.4 Disposable Pens
5.2.5 Jet Injectors
5.3 Geography
5.3.1 North America
5.3.1.1 United States (Value and Volume, 2016 - 2026)
5.3.1.1.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.1.1.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.1.2 Canada (Value and Volume, 2016 - 2026)
5.3.1.2.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.1.2.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.1.3 Rest of North America (Value and Volume, 2016 - 2026)
5.3.1.3.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.1.3.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.2 Europe
5.3.2.1 France (Value and Volume, 2016 - 2026)
5.3.2.1.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.2.1.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.2.2 Germany (Value and Volume, 2016 - 2026)
5.3.2.2.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.2.2.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.2.3 Italy (Value and Volume, 2016 - 2026)
5.3.2.3.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.2.3.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.2.4 Spain (Value and Volume, 2016 - 2026)
5.3.2.4.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.2.4.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.2.5 United Kingdom (Value and Volume, 2016 - 2026)
5.3.2.5.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.2.5.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.2.6 Russia (Value and Volume, 2016 - 2026)
5.3.2.6.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.2.6.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.2.7 Rest of Europe (Value and Volume, 2016 - 2026)
5.3.2.7.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.2.7.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.3 Latin America
5.3.3.1 Mexico (Value and Volume, 2016 - 2026)
5.3.3.1.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.3.1.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.3.2 Brazil (Value and Volume, 2016 - 2026)
5.3.3.2.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.3.2.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.3.3 Rest of Latin America (Value and Volume, 2016 - 2026)
5.3.3.3.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.3.3.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.4 Asia-Pacific
5.3.4.1 Japan (Value and Volume, 2016 - 2026)
5.3.4.1.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.1.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.4.2 South Korea (Value and Volume, 2016 - 2026)
5.3.4.2.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.2.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.4.3 China (Value and Volume, 2016 - 2026)
5.3.4.3.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.3.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.4.4 India (Value and Volume, 2016 - 2026)
5.3.4.4.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.4.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.4.5 Australia (Value and Volume, 2016 - 2026)
5.3.4.5.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.5.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.4.6 Vietnam (Value and Volume, 2016 - 2026)
5.3.4.6.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.6.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.4.7 Malaysia (Value and Volume, 2016 - 2026)
5.3.4.7.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.7.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.4.8 Indonesia (Value and Volume, 2016 - 2026)
5.3.4.8.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.8.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.4.9 Philippines (Value and Volume, 2016 - 2026)
5.3.4.9.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.9.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.4.10 Thailand (Value and Volume, 2016 - 2026)
5.3.4.10.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.10.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.4.11 Rest of Asia-Pacific (Value and Volume, 2016 - 2026)
5.3.4.11.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.11.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.5 Middle-East and Africa
5.3.5.1 Saudi Arabia (Value and Volume, 2016 - 2026)
5.3.5.1.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.5.1.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.5.2 Iran (Value and Volume, 2016 - 2026)
5.3.5.2.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.5.2.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.5.3 Egypt (Value and Volume, 2016 - 2026)
5.3.5.3.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.5.3.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.5.4 Oman (Value and Volume, 2016 - 2026)
5.3.5.4.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.5.4.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.5.5 South Africa (Value and Volume, 2016 - 2026)
5.3.5.5.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.5.5.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.5.6 Rest of Middle-East and Africa (Value and Volume, 2016 - 2026)
5.3.5.6.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.5.6.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
6. MARKET INDICATORS
6.1 Type-1 Diabetes Population (2016 - 2026)
6.2 Type-2 Diabetes Population (2016 - 2026)
7. COMPETITIVE LANDSCAPE
7.1 Company Profiles
7.1.1 Abbott Laboratories
7.1.2 F. Hoffmann-La Roche AG
7.1.3 DexCom, Inc.
7.1.4 Medtronic Plc
7.1.5 Novo Nordisk A/S
7.1.6 Johnson & Johnson
7.1.7 Ascensia Diabetes Care
7.1.8 AgaMatrix
7.1.9 Bionime Corporation
7.1.10 Omnipod
7.1.11 Medisana
7.1.12 Trivida
7.1.13 Rossmax International Ltd
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Diabetes Care Devices Market market is studied from 2012 - 2026.
What is the growth rate of Diabetes Care Devices Market?
The Diabetes Care Devices Market is growing at a CAGR of 5.75% over the next 5 years.
What is Diabetes Care Devices Market size in 2012?
The Diabetes Care Devices Market is valued at 49 Billion USD in 2012.
What is Diabetes Care Devices Market size in 2026?
The Diabetes Care Devices Market is valued at 69 Billion USD in 2026.
Which region has highest growth rate in Diabetes Care Devices Market?
North America is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Diabetes Care Devices Market?
North America holds highest share in 2020.
Who are the key players in Diabetes Care Devices Market?
Medtronic plc, F. Hoffmann-La Roche AG, Novo Nordisk A/S, Abbott Laboratories, DexCom, Inc. are the major companies operating in Diabetes Care Devices Market.
